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Endoscopic Papillary Balloon Dilation for Removal of Choledocholithiasis: 
Indications, Advantages, Complications, and Long-Term Follow-Up Results
Joo Won Chung and Jae Bock Chung
Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, 
Seoul, Korea
Endoscopic papillary balloon dilation (EPBD) is an alterna-
tive method of endoscopic sphincterotomy (EST). Although 
concerns regarding post-procedure pancreatitis have been 
expressed, EPBD has come to be recognized as an effec-
tive and safe method for stone removal in specific cases. 
To analyze the proper indications, ideal methods, complica-
tions, and long-term follow-up results for EPBD, we reviewed 
articles about EPBD located through a search of the PubMed 
data base. We analyzed the ballooning methods, indications, 
results and complications of EPBD among the articles found 
and compared the results with those of EST. We considered 
the authors’ own clinical experience and knowledge in de-
veloping recommendations for EPBD. EPBD showed similar 
effi cacy and safety for the removal of choledocholithiasis to 
that of EST. Although large or multiple stones were diffi cult to 
remove by EPBD, it was safer and easier to apply in patients 
with coagulopathy or abnormal anatomy. To prevent severe 
pancreatitis, excessive ballooning and impractical can-
nulation should be avoided, and precut sphincterotomy or 
adjuvant prophylaxis should be considered. Due to its pres-
ervation of the sphincter of Oddi, EPBD is expected to have 
fewer long-term complications, such as stone recurrence, 
cholangitis and cholecystitis. In conclusion, EPBD appears to 
be safe and effective for the treatment of choledocholithiasis 
with proper selection of ballooning methods and patients. 
(Gut Liver 2011;5:1-14)
Key Words: Choledocholithiasis; Endoscopic papillary bal-
loon dilation; Endoscopic sphincterotomy; Endoscopic papil-
lary large balloon dilation
INTRODUCTION
Before endoscopic retrograde cholangiopancreatography 
(ERCP) and sphincterotomy was introduced in the 1970s, there 
was no other choice than surgery for the treatment of choledo-
cholithiasis except. After Classen et al.1 and Kawai et al.2, first 
introduced endoscopic sphincterotomy (EST), the endoscopic 
removal of stones has been widely accepted as a standard treat-
ment for bile duct stones. Moreover, advances in intraductal 
lithotripsy techniques, such as mechanical basket lithotripsy 
and electrohydraulic lithotripsy, have made it easier to fragment 
large stones. Although the safety of EST has been proven in 
many studies, there are still several limitations on its applica-
tions due to complications: pancreatitis (5.4%), hemorrhage 
(2.0%), perforation (0.3%), cholangitis (1.0%), cholecystitis 
(0.5%), and procedure-related death (0.4%).3 Bleeding after EST 
should be carefully monitored in patients with coagulopathy be-
cause of its high mortality (24.3-22.2%).4-6 Recurrence of stones 
and chronic biliary inflammation were also associated with loss 
of ampulla of Vater function.7-9 There have been many efforts to 
decrease the occurrence of these complications as much as pos-
sible. 
Endoscopic papillary balloon dilation (EPBD) is almost the 
only existing alternative to EST. Although it was not welcomed 
in Western groups because of complications, it has come into 
wide usage in Korea and Japan. Nowadays, an extended tech-
nique of EPBD, endoscopic papillary large balloon dilatation 
(EPLBD) with limited sphincterotomy, is successfully used for 
stone removal. 
To maximize the effects and minimize the complications of 
endoscopic lithotripsy, it is important to recognize the proper 
indications and to apply the technique in a proper manner. 
In this paper, we reviewed articles about EPBD by search-
ing PubMed for making suggestions on the appropriate use of 
EPBD. We analyzed the ballooning methods, indications, results 
and complications of EPBD among the articles, and compared 
the results with those of EST. We considered the authors’ own 
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clinical experience and knowledge in developing recommenda-
tions for EPBD.
EPBD
EPBD was presented for the first time by Staritz et al.10, in 
order to minimize damage to the sphincter of Oddi. Follow-
ing selective deep cannulation, the balloon catheter was placed 
across the papillary orifice and gradually inflated with diluted 
contrast material at a pressure of 8-12 atm. The sphincter was 
adequately dilated if the waist in the balloon completely disap-
peared. The fully inflated balloon was maintained in its position 
for dozens of seconds, and then deflated. The procedure can be 
repeated for complete dilation. Various sizes of balloon catheter 
with 6-15 mm in diameter and 30-40 mm in length can be used 
according to the bile duct diameter and stone size. The veloc-
ity and duration of balloon inflation varied from seconds to 
minutes. After EPBD, the stones were extracted using a Dormia 
basket and/or a retrieval balloon catheter (Fig. 1).
1. Advantages
1) EPBD has several advantages over EST
First, it is less traumatic to the ampullary sphincter, which 
was proven in both animal and human studies. The resected 
specimens of pigs, obtained immediately after EPBD, showed 
only acute inflammation and intramucosal hemorrhage without 
smooth muscle disruption on histological analysis.11 Even after 
several weeks, no architectural distortion or smooth muscle dis-
ruption was noted. In human studies, histological analysis of the 
papilla after EPBD showed only mild to moderate inflammation 
and fibrosis in most patients (80-90%), while no smooth muscle 
disruption nor architectural distortion was observed.12,13 
Second, EPBD may preserve papillary function. After EPBD, 
a mild decrease in papillary function was noted on manometry 
without significant difference. On the other hand, all patients 
who had received EST completely lost papillary function.14 Pap-
illary function began to return to normal only a month after 
EPBD, and the basal and peak pressures of the sphincter of Oddi 
(SO) had significantly recovered by that time as compared with 
the data immediately after EPBD.15 In contrast, SO contraction 
did not recover even after one year after EST.16 Because the 
cutting method was unnecessary, the SO function was not com-
pletely lost after EPBD.
Third, EPBD was shown to be safer for patients with bleeding 
tendency. Coagulopathy under liver cirrhosis, portal hyperten-
sion or administration of anticoagulation is a known risk factor 
for EST-related bleeding.3,17 Because EPBD can avoid an inci-
sion, it may significantly reduce the bleeding risk and mortality 
in patients with liver cirrhosis and coagulopathy.18-20 
Finally, it is favorable for those with abnormal anatomy, such 
as periampullary diverticulum and Billroth II gastrojejunostomy. 
EST is technically difficult in patients with periampullary di-
verticulum or Billroth II gastrojejunostomy because the cutting 
direction of the sphincterotome is not easy to control. Therefore 
Fig. 1. Endoscopic papillary balloon dilation (EPBD) for choledocholithiasis with perivater diverticulum. (A) Duodenoscopic finding shows an am-
pulla of Vater located in a diverticulum. (B) ERCP shows multiple stones in the common bile duct. (C) The guidewire is inserted into the bile duct. 
(D) The 10 mm balloon is gradually inflated with diluted contrast material; inflation is maintained for 30 seconds. (E) X-ray during balloon dila-
tion shows complete disappearance of the sphincter waist. (F) Duodenoscopic finding after EPBD shows a well-visualized common bile duct with 
a large dilated opening of the sphincter of choledochus. (G) ERCP shows a stone grasped by a mechanical lithotripter. (H) Duodenoscopic finding 
shows stones removed from the common bile duct by a Dormia basket.
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a high level of precision in the direction and length of 
the incision is necessary to avoid severe complication. 
In contrast, EPBD requires simple technique to insert the 
balloon catheter into the common bile duct and inflate 
it. Therefore, EPBD is more suitable for the patients with 
periampullary diverticulum or Billroth II gastrojejunos-
tomy.21 Komatsu et al.20 reported on their experience of 
EPBD in 226 patients, and EPBD was successful in 86 pa-
tients (38.0%) with periampullary diverticulum and in two 
patients who had previously undergone Billroth II gastrec-
tomy.
2. Comparison of success rates between EPBD and 
EST for removal of choledocholithiasis (Table 1)
There have been many trials comparing the efficacy and 
safety of EPBD with EST. According to the meta-analysis 
of eight randomized, controlled studies, the overall success 
rate for stone removal was similar in the two groups (94.3% 
vs 96.5%, p=0.2), but the completion rate for the first ses-
sion was significantly higher in the EST group than in 
the EPBD group (79.8% vs 70.0%, p=0.001).22 Mechanical 
lithotripsy was also needed significantly more often in the 
EPBD group in that study (20.9% vs. 14.8%, p=0.01). In 
23% of patients who had failed stone removal with EPBD 
at the first session, the additional EST as a rescue proce-
dure contributed to raising the overall success rate of the 
EPBD group.23 Another study also showed that 9% of the 
EPBD group needed the additional EST.24 
Large or multiple stones are more difficult to remove us-
ing EPBD because the biliary opening is not wide enough. 
The difference of initial success rate between the EPBD and 
EST group was widened in difficult cases, such as stones 
of larger than 10 mm in diameter or four or more stones 
(70.0% vs 83.0%); these cases needed more mechanical 
lithotripsy in the EPBD group (50.0% vs 23.0%, p<0.01).24 
For patients with stones over 10 mm in diameter, EPBD 
required a significantly larger mean number of treatment 
sessions than EST (2.4 vs 1.6, p<0.05).25 Multiple or larger 
stones also required the additional EST in13% of patients, 
while smaller and fewer stones did so in 3% of patients.24 
On the other hand, studies limited to stones smaller than 2.0 
cm in diameter showed that not only overall success rate 
but also initial success rate and requirement of mechanical 
lithotripsy to be similar in both groups.26 Tanaka et al.27 
also reported that EPBD was more effective in cases with 
small-sized (≤15 mm) and small numbers (≤3) of stones 
(100% vs 55.6%, p<0.05). However, Toda et al.28 reported 
that the initial and overall success rates with EPBD were 
comparable to that of EST, regardless of stone size.
When EST was difficult to apply due to periampullary 
diverticulum or prior EST, EPBD was easier and safer than 
EST.29A
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3. Causes for failure to remove choledocholithiasis (Table 2)
The maximum diameter of the stones affects complete stone 
removal, especially when larger than 15 mm in length. Patients’ 
intolerance to the procedure, unrecognized retained stones and 
anatomic problem such as periampullary diverticulum, situs in-
versus and benign distal stricture make it difficult to clear stones 
completely.30 Tortuous common bile duct and distal bile duct 
stricture also interfere with accessing the bile duct.31 In situa-
tions where deep cannulation to the bile duct may have failed, 
precut sphincterotomy was one of the most effective methods. 
Dilating the balloon immediately after the precut sphincter-
otomy became the method of choice before EPBD when deep 
cannulation failed.
4. Complications
1) Post-EPBD pancreatitis
Pancreatitis is one of the most fearful post-ERCP complica-
tion, and occurred in 5-19.8% after EPBD.13,20,30,32,33 Because of 
the significant occurrence of complications, Kozarek34 insisted 
that EPBD should not replace EST. A randomized controlled 
study was finished prematurely due to excessive morbidity in 
the EPBD group (20.0% vs 10.0%).23 Another randomized, con-
trolled multicenter trial was also terminated early at the first 
interim analysis, because two patients died from severe pan-
creatitis as a complication of EPBD.35 Actually, meta-analysis 
demonstrated that post-ERCP pancreatitis occurred more com-
monly in the EPBD group than in the EST group (7.4% vs 4.3%, 
p=0.05).22 The authors thought that the balloon dilation of the 
sphincter of Oddi may have been causing spasm, compression 
and edema of the distal pancreatic duct, resulting in restricted 
flow of pancreatic juice and causing pancreatitis, biliary ob-
struction and cholangitis. To minimize the damage on papilla, 
two different methods of balloon inflation were tried; rapid 
inflation and maintenance for 120 seconds and slow inflation 
and maintenance for 15 seconds. However, the incidences of 
pancreatitis did not differ significantly between the two meth-
ods (73.3% vs 60.6%, p=0.3220).32 A larger balloon (10 to 15 
mm) may cause more compression and edema of the distal 
pancreatic duct, thus precipitating pancreatitis. Smaller bal-
loons of less than 8mm may be safer and more effective in the 
management of bile duct stones, and decrease the incidence of 
pancreatitis.30,36 Balloon dilation in a stepwise fashion, avoiding 
rapid application and excessive pressure, may also contribute to 
decreasing the occurrence of the post-EPBD pancreatitis.37 
According to another study, previous pancreatitis history is 
one of the most significant factor of EPBD related pancreati-
tis (odds ratio [OR], 10.69; 95% confidence interval [CI], 1.57-
72.97).36 In contrast, another study revealed that history of acute 
pancreatitis was not identified as a risk factor, but that contrast 
medium injection to the pancreas was a significant risk factor 
by multivariate analysis (OR, 3.788; 95% CI, 1.036-13.853).32
Table 2. The Causes of Failure of EPBD/EPLBD for Removal of Choledocholithiasis
 Authors
(published yr)
Failure rate,
No. (%)
Causes
Jeong et al.60 (2009) 9/38* (23.9) Maximaum transverse diameter of largest stone 0.077†
Balloon diameter 0.071†
Balloon/stone diameter ratio 0.066†
Mathuna et al.30 (1995) 22/100‡ (22.0)
18/100§ (18.0)
Stone size >15 mm 15.0%
Intolerance of procedure  2.0%
Periampullary diverticulum  1.0%
Situs inversus  1.0%
Benign distal stricture  1.0%
Unrecognized retained stones  2.0%
Bergman et al.24 (1997) 20/101‡ (20.0)
11/101§ (11.0)
Stone size ≥10 mm or number >3 NE
Heo et al.31 (2007) 17/100‡ (17.0)
3/100§ (3.0)
Stone impaction
Difficulty in accessing the bile duct due to very tortuous CBD and distal BD stricture
NE
Attasaranya et al.52
(2008)
5/107‡ (5.0)
5/107§ (5.0)
Multiple stones NE
Large stone (13-30 mm)
Broken basket due to hard stone
Incomplete stone capture
EPBD, endoscopic papillary balloon dilation; EPLBD, endoscopic papillary large balloon dilation; NE, not evaluated; CBD, common bile duct; BD, 
bile duct.
*Application of mechanical lithotripsy or failure to extract stone; †p-value; ‡Failure at first session; §Overall failure.
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As Chinese study showed younger age to be a significant risk 
factor for post-ERCP pancreatitis (OR, 1.59; 95% CI, 1.06-2.39).38 
The progressive decline in pancreatic exocrine function that 
comes with aging may protect older patients from pancreatic 
injury.39 However, there was no significant difference in the 
incidence of post-EPBD pancreatitis between older and younger 
patients.32,36 However, age of younger than 60 years demon-
strated relevance to asymptomatic hyperamylasemia.36
Total procedure time, sex, periampullary diverticulum, me-
chanical lithotripsy, non-dilated bile duct and difficult cannula-
tion were found not to be significant by univariate and multi-
variate analysis.32,36 However, cannulation trauma might result 
in spasm of the sphincter of Oddi and/or hemorrhagic edema-
tous change,33 and was a potential risk factor for asymptomatic 
hyperamylasemia after EPBD (OR, 5.12; 95% CI, 2.79-16.81).36 
In cases of difficult cannulation, minimal EST before standard 
endoscopic balloon dilation may be recommended. Since EST 
may direct the force exerted by the dilating balloon to be di-
rected more toward the common bile duct than the pancreatic 
duct, it may decrease the risk of pancreatitis.40
Several methods were suggested for preventing EPBD-related 
pancreatitis. Gabexate mesylate may reduce the incidence of 
especially moderate or severe pancreatitis.41 Insertion of a pan-
creatic stent,42 epinephrine irrigation after EPBD,43 isosorbide 
dinitrate infusion,44 and injection of botulinum toxin to lower 
the pancreatic sphincter pressure45 may augment pancreatic 
drainage. However these adjuvant interventions also present 
potential for complications, and their time or cost-effectiveness 
remains questionable. 
2) Bleeding 
As stated above, EPBD has little theoretical risk of bleed-
ing, and clinically significant bleeding which was defined as 
continuous bleeding after procedure or conditions requiring 
transfusion and additional intervention for hemostasis, is rarely 
reported after EPBD. Meta-analysis showed no episode of bleed-
ing in the EPBD group, whereas it was noted in 2.0% of the 
EST group.22 In case of self-limited or endoscopically controlled 
bleeding, the incidence was significantly higher in EST group 
(27%) than in EPBD group (10.5%).35
3) Perforation
Although meta-analysis showed no significant difference in 
the perforation rate between the EPBD and EST groups,22 only 
one study reported two retroperitoneal perforations after EBPD,24 
whereas four studies reported five perforations after EST.24,28,35,46 
EPBD does not appear to increase the rate of perforation com-
pared with EST.
4) Abdominal pain during infl ation of the balloon
During inflation of the balloon, 23.5-50% of patients felt 
abdominal pain or discomfort. However this adverse effect was 
temporary and got better by a reduction in balloon pressure and 
duration.20,26,30
5) Cholangitis and cholecystitis
Acute cholangitis within 15 days after procedure occurred 
only in the EST group (12.5%).27 Acute cholecystitis developed 
more often in the EST group than in the EPBD group (9.9% vs 
1.3%, p<0.05). This may be explained by loss of sphincter func-
tion after EST, which enables bacteria colonization from the 
intestine into the biliary system.24
6) Gallstone ileus
Gallstone ileus is an extremely rare complication of ERCP and 
EST.47 Advanced age, a history of prior small bowel resection 
and stricture are a possible causes of intestinal obstruction by 
the passed stone via widened orifice of the sphincter.48 Unlike 
EST, EPBD can preserve the sphincter of Oddi and thus decrease 
the risk of gallstone ileus. However, there is the possibility of 
small bowel obstruction by the stones extracted during the 
ERCP. Thus, it is recommended that large stones be removed 
after pulverization by mechanical lithotripsy. 
5. Long-term follow-up results (Table 3)
Little is known about long-term complications of EPBD. A 
Japanese study with a mean overall follow-up duration of 9.3 
years (7.0-12.1 years) demonstrated that 22 patients (12.1%) of 
182 experienced 33 biliary complications during the follow-up 
period; stone recurrences in 13 patients (7.1%), stone migration 
from the gallbladder in 5 patients (2.7%), acute cholangitis in 10 
patients (5.5%), acute cholecystitis in 4 patients (2.2%), and fa-
tal gallstone pancreatitis in one patient (0.5%).49 Approximately 
85% of recurring bile duct stones occurred within 3 years after 
EPBD. All recurring stones were bilirubinate, and the majority 
of patients (92.3%) with stone recurrence did not have pneu-
mobilia. Previous cholecystectomy (OR, 4.813; 95% CI, 1.237-
18.726), dilated bile duct of more than 15 mm in width (OR, 
4.433; 95% CI, 1.084-18.117) and no confirmation of clean duct 
using IDUS (OR, 11.197; 95% CI, 2.170-57.771) were significant 
risk factors for stone recurrence according to multivariate anal-
ysis. Although periampullary diverticulum was noted as a risk 
factor in another study with mid-term follow-up period (mean 
23 moths),50 it was not significant in this long-term follow-up 
study. Age, sex, large stone, multiple stones, multiple endo-
scopic sessions and mechanical lithotripsy were not associated 
with stone recurrence in this study, either. Between the patients 
younger and older than 85 years of age, there was no signifi-
cantly difference in overall complications, such as cumulative 
stone recurrence rate (7.1% vs 7.7%, p=0.6225), acute cholan-
gitis (1.9% vs 2.6%, p=0.7711) and acute cholecystitis (1.1% 
vs 2.6%, p=0.4594) during the follow-up period (mean, 61.1 
months vs 39 months).51 Remnant GB stone was one of the fac-
tors related with biliary stone recurrence. During a mean follow-
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up of 2,214 days, recurrence was observed more frequently in 
the group with GB stones.
There were several comparative studies of mid-term and 
long-term complications between the EPBD and EST groups. 
During a mean follow-up of 16 months, common bile duct 
stones recurred at a similar rate in both groups (5.8% at 22-
26 weeks vs 7.5% at 12-48 weeks).26 Another study compared 
early, mid-term and late complications of the procedure. Within 
1 year of follow-up, bile duct stones recurred more frequently 
in the EPBD group (25.0%) than in the EST group (6.3%). On 
the contrary, if the follow-up period was longer than one year, 
stone recurrences were more common in EST group (26.7%) 
than the EPBD group (6.3%). A larger post-EST papillary open-
ing facilitated spontaneous passage of small biliary duct stones. 
However, other factors may contribute to stone recurrence in 
long-term follow-up after EST, for example repeated reflux of 
intestinal juice to the bile duct from the duodenum. Preserva-
tion of sphincter function might prevent the stone recurrence 
beyond the early post procedure period.27 After one year, SO 
function was not restored in the EST group, while it was signifi-
Table 3. Long Term Follow-Up Results of EPBD
Authors
(published yr)
Patients’ factors Initial procedure Follow-up results
Patients no.
Stone 
size, 
mm
Mechanical
lithotripsy, 
No. (%)
Complete
ratio of
stone
clearance, 
No. (%)
Follow-up
duration, mo
Bile duct 
stone recur-
rence, 
No. (%)
Time to 
recurrence
Other complications
Minami et al.14
(1995)
 20 - - 20 
(100)
21.5±6.2 1 
(5.0)
- No complication
Yasuda et al.16
(2001)
235 12.7
(4-47)
35 
(15.0)
235 
(100)
36.3
(12-67)
23 
(10.0)
- Acute cholangitis 0
Natsui et al.25
(2002)
 70 9.2
(3-22)
29 
(41.4)
65
 (92.9)
30
(12-54)
3 
(4.4)
Acute cholecystitis 1 (3.6%)
Ueno et al.50
(2003)*
169 11.8 - 162 
(95.8)
23
(12-53)
13
 (13.3)
12.5 mo
(6-25)
Not commented
Lin et al.26
(2004)
 51 0.8±0.6 1 
(2.0)
48 
(94.1)
16±3 3 
(5.8)
22-26 wk Not commented
Vlavianos et al.59
(2003)
103 ≤5 (26.0%)
6-9 (36.0%)
≥10 (38.0%)
7 
(6.8)
90
(87.4)
12 2 
(1.9)
- Acute cholangitis 2 (1.9%)
Acute cholecystitis 2 (1.9%)
Acute pancreatitis 1 (1.0%) 
Tanaka et al.27
(2004)
 16 10.2±3.5
(5-15)
8 
(50.0)
16
(100)
61.5
(54-76)
4
 (25.0)
- Acute cholecystitis 0
Ito et al.51
(2008)
 74
(Age≥85)
10.3±4.7 42 
(57.0)
67 
(91.0)
39.1 3 
(7.7)
- Acute cholangitis 1 (2.6%)
Acute cholecystitis 1 (2.6%)
332
(Age<85)
7.3±4.3 87 
(26.0)
317
 (95.0)
61.1 19 
(7.1)
- Acute cholangitis 5 (1.9%)
Acute cholecystitis 3 (1.1%)
Ohashi et al.49
(2009)†
212 10.6±5.4
(2-30)
95 
(52.2)
204 
(96.2)
9.3±2.4 yr
(0.2-12.1)
13 
(7.1)
1.7±1.7 yr
(0.4-6.3)
Acute cholangitis 10 (5.5%)
Acute cholecystitis 4 (2.2%)
Acute pancreatitis 1 (0.5%)
Mortality 1 (0.5%)‡
Kojima et al.61
(2010)
453 7.7±3.5 144
 (31.7)
448
(99.0)
2,214 day
(336-4,442)
31
(6.8)
- Not commented
The size of the balloon used in the endoscopic papillary balloon dilation (EPBD) procedures was approximately 8 mm, except in studies performed 
by Lin et al. (8 to 12 mm) and Vlavianos et al. (10 mm).
All of the patients were followed up, except in the studies of Natsui et al. (68, 97.1%), Ueno et al. (98, 58%), and Ohashi et al. (182, 89.2%).
Prognostic factors were determined by multivariate analysis.
*Bile duct diameter>20 mm (relative risk 6.83) and diverticulum (relative risk 6.88); †Previous cholecystectomy (odds ratio 4.8), bile duct diameter 
>15 mm (odds ratio 4.4) and confirmation using IDUS (odds ratio 11.2); ‡Mortality was related to gallstone pancreatitis.
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cantly recovered in the EPBD group.16 The preservation of SO 
function prevents the later biliary complications. When follow-
ups were done for about 3 years in the EPBD and EST groups, 
pneumobilia appeared at a significantly higher rate in the EST 
group (40.0%) than in the EPBD group (8.9%) (p<0.01). Simi-
larly, cholecystitis was observed significantly more often in the 
EST group (18.8%) than in the EPBD group (4.7%) (p<0.05). 
Significant difference was found between the two groups with 
the regard to the cumulative incidence of biliary complications 
(p<0.05).
EPLBD 
Because EPBD showed limited success rate in cases of large 
bile duct stones, EPLBD was attempted in 2003 by Ersoz et al.40 
Prior to balloon dilation of the sphincter, a small sphincteroto-
my incision was made from the orifice of the papilla proximally 
to the transverse fold. A large-diameter balloon catheter (12-20 
mm) was introduced into the bile duct and gradually inflated 
with diluted contrast medium until the waist of balloon was 
disappeared, and maintained in position for a dozens of seconds 
(Fig. 2).
EPLBD enlarged the biliary orifice enough to facilitate re-
moval of multiple and larger stones, resulting in a decreased use 
of mechanical lithotripsy and increased rate of stone removal. 
According to reports on the efficacy of EPLBD with EST, the 
complete rates of bile duct stone at first and final session were 
72-100% and 95-100%, respectively (Table 4).31,40,52-58
Even though the stone is large, the less mechanical lithotripsy 
was needed with large diameter balloon plus sphincterotomy. 
The largest stone in the studies was up to 30 mm in diam-
eter.52,56 When EPLBD with a 13 mm sized balloon was used to 
remove the 10-30 mm sized stones, the overall success rate was 
95% as usual, but mechanical lithotripsy was required in 27.0% 
of the cases.52 On the other hand, when larger balloons of up 
to 15 mm in size were used for the removal of 6-30 mm sized 
stones, the overall success rate was 95% and the mechanical 
lithotripsy was required in only 4.5% of the cases.56
The efficacy of stone removal in EPLBD plus EST as com-
pared with that of EST alone was similar. The initial success 
rate of EPLBD plus EST was higher than that of EST (96.2% vs 
85.4%), which showed marginal statistical significance (p=0.057). 
Stone fragmenting by mechanical lithotripsy disturbed complete 
clearance and prolonged the procedure time. Because combin-
ing of EPLBD and EST reduces the need for mechanical litho-
tripsy (5.7% vs 25.0%, p<0.01), it effectively reduces the total 
procedure time (31.6±8.8 seconds vs 40.2±16.3 seconds, p<0.05) 
and radiation exposure (13.1±6.6 seconds vs 21.9±14.7 seconds. 
p<0.05).57 The complete duct clearances in cases of stones larger 
than 15 mm were not significantly different between EPLBD 
plus EST and EST alone (94.4% vs 96.7%, p=0.569) (Table 5).31 
Mechanical lithotripsy or repetitive procedure were in fact less 
Fig. 2. Endoscopic papillary large balloon dilation (EPLBD) with limited sphincterotomy. (A) Duodenoscopic finding shows an ampulla of Vater. 
(B) ERCP shows a large stone in the common bile duct and percutaneous transhepatic biliary drainages placed in the right hepatic lobe. (C) A pull-
type sphincterotome is inserted into the bile duct along the guidewire. The biliary sphincter is incised by electrocautery with the bowed cutting 
wire. (D, E) The 15 mm sized large balloon is gradually inflated with diluted contrast material; inflation is maintained for 30 seconds. (F) Duode-
noscopic finding after EPLBD shows a well-visualized common bile duct with a large, dilated opening of the sphincter of choledochus. (G) ERCP 
shows a large stone grasped by a mechanical lithotripter. (H) Duodenoscopic finding shows stones removed from the common bile duct by a Dor-
mia basket.
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necessary in EPLBD plus EST. EPLBD may decrease the risks of 
EST and clear away larger stones in cases with difficult anato-
mies. 
Theoretically, it is feared that large size balloon dilation could 
cause perforation or fatal pancreatitis, however there is only one 
report of cystic duct perforation52 and none of fatal pancreatitis. 
On the other hands, in patients with coagulopathy who have 
a great risk of bleeding after EST, compression by ballooning 
seems to be effective for hemostasis. There are some concerns 
that the sphincter of Oddi could be destroyed by large sized-
balloon.  For lack of long-term results, we have little informa-
tion of stone recurrence or cholangitis after EPLBD. 
EPLBD plus EST be applied to anatomically difficult cases 
without critical complications but should also be confirmed by 
long-term follow-up studies.
CONCLUSIONS
EPBD and EPLBD seem to be safe and effective for the treat-
ment of bile duct stones although mechanical lithotripsy is 
more frequently needed than in EST. Due to the preservation 
of SO function, EPBD seems to present less at risk of long term 
complications, such as stone recurrence, cholangitis and chole-
cystitis than EST. Although concerns were presented about post-
procedure pancreatitis, recent reports have demonstrated that 
EPBD can be successfully and safely used for removal of small 
size and small unmber of stones. In patients with a higher risk 
of bleeding or an abnormal anatomy (periampullary diverticu-
lum, Billrothe II gastrojejunostomy and prior EST status), EPBD 
is safer than EST. The most important ways to avoid severe 
complications are proper balloon size according to bile duct 
width and a wake-up not to excessively increase balloon pres-
sure. When there are high risk factors of post ERCP panceatitis 
(young patients, previuos history of pancreatitis, and so on), 
balloon size should be as small as possible and adjuvant pro-
phylaxis (pancreatic duct stent, gabexate mesylate, and so on) 
could be considered. In case of difficult cannulation, impractical 
cannulation should be avoided and minimal EST before bal-
loon dilation is recommended. EPLBD could be useful adjuvant 
in patients with very large bile duct stones. We summarize the 
indications, methods, and complications of EPBD and EPLBD in 
Table 5. In the near future, making a guide-line for endoscopic 
Table 4. Comparisons between EPLBD with EST (Group A) and EST Alone (Group B) for Removal of Choledocholithiasis
Authors
(published 
yr)
Method Patients’ factors Results
Complications
Group
Balloon
size, 
mm
Age,
yr
Sex,
M/F
Periampul-
lary
diverticu-
lum,
No. (%)
Stone 
no.
Stone 
size,
mm
Mechanical 
lithotripsy, 
No. (%)
Complete 
ratio at first 
session, No. 
(%)
Complete 
ratio at the 
end of 
session, 
No. (%)
Heo et al.31 
(2007)
A 
(n=100)
12-20 64.4±12.8 48/52 49 (49.0) 2.7±2.7 16±0.7 8 (8.0) 83 (83.0) 97 (97.0) Pancreatitis 4 (4.0%)
Cholecystitis 1 (1.0%)
Bleeding 0
Perforation 0
B 
(n=100)
- 62.8±15.7 50/50 45 (45.0) 2.2±1.9 15±0.7 9 (9.0) 87 (87.0) 98 (98.0) Pancreatitis 4 (4.0%)
Bleeding 2 (2.0%)
Cholecystitis 1(1.0%)
Perforation 0
Itoi et al.57
(2009)
A 
(n=53)
15, 18, 
20
75.3±12.8 20/33 25 (47.2) 3.2±3.1 14.8±3.5 3 (5.7)* 51 (96.2) 53 (100) Pancreatitis 1 (1.9%)
Cholangitis 1 (1.9%)
Bleeding 0
Perforation 0
B 
(n=48)
- 72.6±14.6 28/30 28 (58.3) 3.0±2.8 15.3±3.2 12 (25.0)* 41 (85.4) 47 (98.0) Pancreatitis 2 (4.1%)
Cholangitis 1 (2.1%)
Bleeding 0
Perforation 0
Kim et al.62
(2009)
A 
(n=27)
15, 16.5,
18
70.3±8.7 10/15  9 (33.3) 2.2±1.3 20.8±4.1 9 (33.3) 23 (85.0) 27 (100) Bleeding 4 (15.0%)
Pancreatitis 0
Cholangitis 0
Perforation 0
B 
(n=28)
- 69.8±9.2 11/14 10 (35.7) 2.3±1.2 21.3±5.2 9 (32.1) 23 (86.0) 28 (100) Bleeding 2 (7.0%)
Pancreatitis 0
Cholangitis 0
Perforaiton 0
EPLBD, endoscopic papillary large balloon dilatation; EST, endoscopic sphincterotomy.
*p<0.01.
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management of bile duct stones according to the individual pa-
tient’s characteristics (e.g., age, coagulopathy, previous history 
of EST, pancreatitis and gastric operation) and bile duct stone 
characteristics (e.g., size, number) will be helpful to gastroenter-
ologist.
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